Fever and Infection Prevalence in Hematology-Oncology Hospitalized Patients: A Single-Center Retrospective Study
- 1 Internal Medicine Department, Centro Hospitalar de Sao Joao, Porto, Portugal
- 2 Departmentof Hematology-Oncology Clinic, Instituto Português de Oncologia (IPO), Porto, Portugal
- 3 Departmentof Hematology-Oncology Clinic, Instituto Português de Oncologia (IPO), Porto, Portugal
Abstract
Fever is prevalent in hospitalized patients. In hematology-oncology patients , it is related with infection, a disease manifestation or a consequence of immunological dysfunction. This single-center retrospective study aims to determine fever prevalence, describe its causes and evaluate the impact of infection on mortality. We reviewed clinical records of 222 patients admitted to the hospital in three random months of 2015. Around 35% of all hospitalizations were complicated by fever, 42 . 5% of unknown origin. 90 . 4% were under treatment. Around 81% did antibiotics, most commonly piperacil lin/tazobactam, for around 11 days. 41% changed antibiotics due to fever persistence or microbiological results. The diagnostic yield of microbiological tests was 25%; in 66 . 7%, a Gram-negative microorganism was isolated. We didn’t find an association between infection and mortality. We conclude that fever is common in our hematology-oncology clinic and that the team is trained to assume infection; empirical treatment is in accordance with international recommendations.
- Kluger, M. and Rothenburg, B. (1979) Fever and Reduced Iron: Their Interaction as a Host Defense Response to Bacterial Infection. Science, 203, 374-376. https://doi.org/10.1126/science.760197
- Earn, D.J., Andrews, P.W. and Bolker, B.M. (2014) Population-Level Effects of Suppressing Fever. Proceedings of the Royal Society of London B, 281, 1-5. https://doi.org/10.1098/rspb.2013.2570
- Evans, S.S., Repasky, E.A. and Fisher, D.T. (2015) Fever and the Thermal Regulation of Immunity: The Immune System Feels the Heat. Nature Reviews Immunology, 15, 335-349. https://doi.org/10.1038/nri3843
- McGowan Jr., J.E., Rose, R.C., Jacobs, N.F., Schaberg, D.R. and Haley, R.W. (1987) Fever in Hospitalized Patients. American Journal of Medicine, 82, 580-586. https://doi.org/10.1016/0002-9343(87)90103-3
- Klastersky, J. (2004) Management of Fever in Neutropenic Patients with Different Risks of Complications. Clinical Infectious Diseases, 39, S32-S37. https://doi.org/10.1086/383050
- Engelhart, S., Glasmacher, A., Exner, M. and Kramer, M.H. (2002) Surveillance for Nosocomial Infections and Fever of Unknown Origin among Adult Hematology-Oncology Patients. Infection Control & Hospital Epidemiology, 23, 244-248. https://doi.org/10.1086/502043
- Mikulska, M., Viscoli, C., Orasch, C., Livermore, D.M. and Averbuch, D. (2014) Aetiology and Resistance in Bacteraemias among Adult and Paediatric Haematology and Cancer Patients. Journal of Infection, 68, 321-331. https://doi.org/10.1016/j.jinf.2013.12.006
- Aynioglu, A., Mutlu, B. and Hacihanefioglu, A. (2016) A Comparison of the Efficacy of Piperacillin-Tazobactam and Cefoperazone-Sulbactam Therapies in the Empirical Treatment of Patients with Febrile Neutropenia. Revista Espanola de Quimioterapia, 29, 69-75.
- Boada Burutaran, M., Guadagna, R., Grille, S., Stevenazzi, M., Guillermo, C. and Diaz, L. (2014) Results of High-Risk Neutropenia Therapy of Hematology-Oncology Patients in a University Hospital in Uruguay. Revista Brasileira de Hematologia e Hemoterapia, 37, 28-33. https://doi.org/10.1016/j.bjhh.2014.11.012
- Piukovics, K., Terhes, G., Lázár, A., Tímár, F., Borbényi, Z. and Urbán, E. (2015) Evaluation of Bloodstream Infections during Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience. European Journal of Microbiology and Immunology, 5, 199-204. https://doi.org/10.1556/1886.2015.00021
- Winston, D.J., Lazarus, H.M., Beveridge, R.A., Hathorn, J.W., Gucalp, R., Ramphal, R., et al. (2001) Randomized, Double-Blind, Multicenter Trial Comparing Clinafloxacin with Imipenem as Empirical Monotherapy for Febrile Granulocytopenic Patients. Clinical Infectious Diseases, 32, 381-390. https://doi.org/10.1086/318500